Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Study calls for optimized medical treatment for older patients with advanced lung cancer

Study calls for optimized medical treatment for older patients with advanced lung cancer

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Researchers discover 93-gene signature associated with EGFR mutations in lung cancer tumors

Retreating with gefitinib may benefit non-small cell lung cancer patients

Retreating with gefitinib may benefit non-small cell lung cancer patients

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Winners of Paul Marks Prize 2009

Winners of Paul Marks Prize 2009

miR-21 molecule plays early and important role in nonsmoking lung cancer

miR-21 molecule plays early and important role in nonsmoking lung cancer

Cancer drugs erlotinib and gefitinib might treat alcoholism

Cancer drugs erlotinib and gefitinib might treat alcoholism

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib just as effective as chemotherapy for lung cancer

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Report says cancer clinicians should understand and consider the economic impact of new interventions

Report says cancer clinicians should understand and consider the economic impact of new interventions

Targeted therapy can improve outcomes for lung tumors

Targeted therapy can improve outcomes for lung tumors

How tumors respond to EGFR inhibitors

How tumors respond to EGFR inhibitors

Combination treatment cures mice of a very aggressive human breast tumor

Combination treatment cures mice of a very aggressive human breast tumor

New mechanism identified for resistance to targeted lung cancer drugs

New mechanism identified for resistance to targeted lung cancer drugs

New methods for treating lung cancer cells that have become resistant to new anti-cancer agents

New methods for treating lung cancer cells that have become resistant to new anti-cancer agents